Development Process

	1991 SungenBio started to develop r-hirudi in 1991.
	2003 SungenBio signed the cooperation agreement of “Anticoagulant drugs—R-hirudi”with life sciences at Peking University.And r-hirudi was produced by gene engineering fermentation in 2003, becoming the project of national.
	Hirudin™ obtained national patent certification：Method of producing hirudin mutant HV2-Lys47 and its special expression vector and strain. Patent number：ZL03109244.6.
	2004 SungenBio, jointly with Peking University School of Life Sciences,Peking University Health Science Center and the special invited Chinese cardiologists , convened a demonstration meeting of R-hirudin clinical indications in Beijing to discuss the in-depth study of R-hirudin project.
	2015 SungenBio invited the experts of Peking University School of Life Sciences, China Medical University and Shenyang Pharmaceutical University to convened a seminar of Hirudin blood collection tube coating and oral nano-preparation application.